News & Updates

Show Multimedia Only

Vedolizumab better used in early- vs late-stage Crohn’s disease

13 Dec 2025

In patients with Crohn’s disease (CD), initiating treatment with vedolizumab early than late in the disease course may lead to better safety and efficacy outcomes, according to a phase IV open-label cohort study.

Vedolizumab better used in early- vs late-stage Crohn’s disease

13 Dec 2025

Outpatient use of nirmatrelvir/ritonavir cuts risk of severe COVID

13 Dec 2025

Outpatient use of nirmatrelvir/ritonavir lowers the risk of severe COVID-19-related outcomes, regardless of age or vaccination status, in a large, nationally representative cohort study in Taiwan, highlighting the importance of early antiviral treatment in ageing and unvaccinated populations.

Outpatient use of nirmatrelvir/ritonavir cuts risk of severe COVID

13 Dec 2025

Nirmatrelvir/ritonavir prescriptions higher in certain demographic, socioeconomic groups

13 Dec 2025

Prescribing patterns for nirmatrelvir/ritonavir within a healthcare system in Eastern Massachusetts, US, reveal significant demographic and socioeconomic differences, according to a retrospective study.

Nirmatrelvir/ritonavir prescriptions higher in certain demographic, socioeconomic groups

13 Dec 2025

Adding NMV/r to COVID-19 formulary cuts medication costs, shortens hospital stays

13 Dec 2025

A study presented at IDWeek 2025 demonstrates substantial medication cost savings, shorter hospital stays, reduced treatment duration, and lower rates of progression to severe disease when nirmatrelvir-ritonavir (NMV/r) was added to the acute care formulary for treating elderly patients with mild-to-moderate COVID-19.

Adding NMV/r to COVID-19 formulary cuts medication costs, shortens hospital stays

13 Dec 2025

Nirmatrelvir/ritonavir cost-effective for mild-to-moderate COVID-19

13 Dec 2025

Treatment with nirmatrelvir/ritonavir (NMV/r) provides good value for money because of its health benefits for patients with mild-to-moderate COVID-19 who are at an increased risk of progressing to severe disease, according to the results of a systematic literature review of economic value.

Nirmatrelvir/ritonavir cost-effective for mild-to-moderate COVID-19

13 Dec 2025

Mortality benefits seen with nirmatrelvir/ritonavir monotherapy

13 Dec 2025

Treatment with nirmatrelvir/ritonavir significantly reduced mortality risk among hospitalized COVID-19 patients compared with the combined molnupiravir and nirmatrelvir/ritonavir regimen, according to a target trial emulation study presented at IDWeek 2025.

Mortality benefits seen with nirmatrelvir/ritonavir monotherapy

13 Dec 2025

Reduced symptom burden, faster recovery with NMV/r vs placebo

13 Dec 2025

Treatment with nirmatrelvir/ritonavir (NMV/r) reduced both the duration and severity of COVID-19 symptoms, based on patients’ overall perception of their symptom burden, and facilitated a faster return to normal health and activities, as demonstrated in a recent exploratory analysis.

Reduced symptom burden, faster recovery with NMV/r vs placebo

13 Dec 2025

Single-dose CYD-TDV does not protect vs. dengue in both dengue-naïve and monotypic-profile children

13 Dec 2025

In a recent longitudinal, prospective, population-based cohort study done in Cebu, Philippines, a single dose of CYD-TDV did not immunize against RT-PCR-confirmed dengue in a healthy cohort of children who had, at most, one previous dengue virus (DENV) infection by serostatus at the outset of the study.

Single-dose CYD-TDV does not protect vs. dengue in both dengue-naïve and monotypic-profile children

13 Dec 2025

Bedtime snacking may worsen T1D control in kids

12 Dec 2025

In young children with type 1 diabetes (T1D), bedtime snacking appears to result in higher nocturnal glucose values and reduced time in range (TIR), without decreasing the frequency of hypoglycaemia, according to a randomized controlled crossover trial.

Bedtime snacking may worsen T1D control in kids

12 Dec 2025

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

12 Dec 2025 by

Treatment with semaglutide appears to improve glycaemic control and weight outcomes in patients with schizophrenia receiving second-generation antipsychotics, as shown in a study.

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

12 Dec 2025

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Vedolizumab better used in early- vs late-stage Crohn’s disease

Vedolizumab better used in early- vs late-stage Crohn’s disease

Outpatient use of nirmatrelvir/ritonavir cuts risk of severe COVID

Outpatient use of nirmatrelvir/ritonavir cuts risk of severe COVID

Nirmatrelvir/ritonavir prescriptions higher in certain demographic, socioeconomic groups

Nirmatrelvir/ritonavir prescriptions higher in certain demographic, socioeconomic groups

Adding NMV/r to COVID-19 formulary cuts medication costs, shortens hospital stays

Adding NMV/r to COVID-19 formulary cuts medication costs, shortens hospital stays

Nirmatrelvir/ritonavir cost-effective for mild-to-moderate COVID-19

Nirmatrelvir/ritonavir cost-effective for mild-to-moderate COVID-19

Mortality benefits seen with nirmatrelvir/ritonavir monotherapy

Mortality benefits seen with nirmatrelvir/ritonavir monotherapy

Reduced symptom burden, faster recovery with NMV/r vs placebo

Reduced symptom burden, faster recovery with NMV/r vs placebo

Single-dose CYD-TDV does not protect vs. dengue in both dengue-naïve and monotypic-profile children

Single-dose CYD-TDV does not protect vs. dengue in both dengue-naïve and monotypic-profile children

Bedtime snacking may worsen T1D control in kids

Bedtime snacking may worsen T1D control in kids

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics